Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity
Cancer Immunology, Immunotherapy · 19.08.2025 · 74 (9)
DOI: 10.1007/s00262-025-04111-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 19.08.2025. Verfasst von Yoichiro Narikawa und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kit…. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Inosine, CTLA-4 Antigen, Immunotherapy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Inosine, a bacterial metabolite and agonist of the adenosine A2A receptor, modulates antitumor immunity. However, its precise effects on immune checkpoint inhibitors remain unclear. This study aimed to evaluate the impact of inosine on the efficacy of anti-programmed cell death protein 1 (PD-1) therapy and explore strategies to counteract any potential inhibitory effects. In in vitro co-culture systems, inosine selectively suppressed cancer cell growth without impairing T-cell viability. In a murine subcutaneous tumor model, inosine treatment reduced tumor growth and was associated with elevated interferon-gamma levels in the tumor microenvironment, along with increased infiltration by tumor-infiltrating lymphocytes and enhanced splenic CD4⁺ and CD8⁺ T-cell frequencies. However, the combination of inosine with anti-PD-1 therapy attenuated the antitumor effect and increased cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) expression in splenic T cells compared to levels after anti-PD-1 monotherapy. To overcome this inhibitory effect, we tested whether adding an anti-CTLA-4 antibody could restore antitumor immunity. Notably, the combination of inosine with both anti-PD-1 and anti-CTLA-4 antibodies significantly enhanced antitumor efficacy. These findings suggest that inosine may synergize with dual ICI therapy and represent a promising adjunct to improve immunotherapeutic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kita-Karasuyama, Setagaya-Ku, Tokyo, 157-8577, Japan.
- Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan.
- Pharmacological Research Center, Showa Medical University, Tokyo, Japan.
- Department of Otorhinolaryngology-Head and Neck Surgery, Showa Medical University School of Medicine, Tokyo, Japan.
- Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
- Division of Pharmacology, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa Medical University, Tokyo, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Narikawa, Y., Kuramasu, A., Hosonuma, M., Murayama, M., Funayama, E., Sasaki, A., Baba, Y., Toyoda, H., Isobe, J., Tajima, K., Nakashima, R., Sasaki, A., Maruyama, Y., Yamazaki, Y., Shida, M., Tsurui, T., Hirasawa, Y., Ariizumi, H., Ishiguro, T., …, & Yoshimura, K. (2025). Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity. Cancer Immunology, Immunotherapy, 74(9). https://doi.org/10.1007/s00262-025-04111-2
Vancouver
Narikawa Y, Kuramasu A, Hosonuma M, Murayama M, Funayama E, Sasaki A, et al. Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity. Cancer Immunology, Immunotherapy. 2025;74(9). doi:10.1007/s00262-025-04111-2
BibTeX
@article{Narikawa2025,
author = {Narikawa, Yoichiro and Kuramasu, Atsuo and Hosonuma, Masahiro and Murayama, Masakazu and Funayama, Eiji and Sasaki, Akiko and Baba, Yuta and Toyoda, Hitoshi and Isobe, Junya and Tajima, Kohei and Nakashima, Rie and Sasaki, Aya and Maruyama, Yuki and Yamazaki, Yoshitaka and Shida, Midori and Tsurui, Toshiaki and Hirasawa, Yuya and Ariizumi, Hirotsugu and Ishiguro, Tomoyuki and Suzuki, Risako and Ohkuma, Ryotaro and Kubota, Yutaro and Sambe, Takehiko and Tsuji, Mayumi and Wada, Satoshi and Horiike, Atsushi and Kobayashi, Shinichi and Tsunoda, Takuya and Kobayashi, Sei and Kobayashi, Hitome and Oguchi, Tatsunori and Shimane, Toshikazu and Kiuchi, Yuji and Yoshimura, Kiyoshi},
title = {Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
volume = {74},
number = {9},
doi = {10.1007/s00262-025-04111-2}
}
EUVIMED